We are pleased to announce that the project titled “Personalized endothelial diagnostics in anticancer treatment; towards modern vasculooncology” [acronym: ADEVASCO (Aptamer-Based Diagnosis of Endothelium in Vasculooncology)], which received a positive evaluation in the competition under the Virtual Research Institute (WIB), has been granted funding. The agreement was signed on September 27, 2024, and the project will commence on January 1, 2025.

The project will be carried out by a consortium comprising the following institutions:

• Jagiellonian University (Project Leader),
• Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Sciences in Wrocław,
• Institute of Animal Reproduction and Food Research Polish Academy of Sciences in Olsztyn,
• Medical University of Gdańsk,
• Maria Sklodowska-Curie National Research Institute of Oncology in Gliwice,
• Warsaw University of Technology.

The ADEVASCO project aims to develop an innovative diagnostic technology enabling the early detection of vascular endothelial dysfunction caused by oncological therapies. This technology, based on electrochemical aptasensors, will facilitate personalized assessment of the risk of cardiovascular complications associated with cancer treatment.

The developed solution has the potential to become a breakthrough in diagnostics accompanying cancer therapy, as well as in modern vasculooncology. The project will be carried out by a team of scientists from the Warsaw University of Technology, led by PhD Eng. Mariusz Pietrzak, Professor at WUT. Key work will be conducted in the CEZAMAT laboratories at the Warsaw University of Technology.

The selection of the ADEVASCO project in the prestigious WIB competition confirms its innovative character and its importance for the advancement of modern medical diagnostics. The total funding allocated to the project amounts to over 78 million PLN.